H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Galera Therapeutics to $6 from $10 and keeps a Buy rating on the shares. The analyst cites dilution from the recent equity financing for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRTX:
- Biotech Alert: Searches spiking for these stocks today
- Galera Therapeutics price target lowered to $12 from $18 at Citi
- Galera Therapeutics announces presentation of analysis of Phase 3 ROMAN trial
- Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts